Physician profile
Michael A Papper
NPI 1053432104
$9,839.39
in general payments reported to CMS, 2019-2025
34 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $430 · 2021: $1,753 · 2022: $2,270 · 2023: $1,342 · 2024: $1,967 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,347 · Education: $39.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,347.37 |
| Education | $39.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,041.99 | 2020-2025 | |
| Janssen Biotech, INC. | $960.17 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $803.39 | 2021-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $749.67 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $723.29 | 2020-2025 | Xifaxan, Trulance |
| Celgene Corporation | $470.73 | 2021-2024 | Zeposia |
| Pfizer INC. | $443.65 | 2021-2025 | |
| Madrigal Pharmaceuticals | $422.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $317.34 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $204.09 | 2020-2024 | |
| Intercept Pharmaceuticals, INC. | $186.38 | 2021-2025 | Ocaliva |
| Evoke Pharma, INC. | $167.76 | 2021-2023 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $161.84 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $143.72 | 2024-2025 | Omvoh |
| Intuitive Surgical, INC. | $133.18 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $123.96 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $101.62 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $89.77 | 2021-2022 | |
| Ucb, INC. | $81.71 | 2020-2022 | |
| Vivus LLC | $75.60 | 2025 | Pancreaze |
| Ardelyx, INC. | $67.27 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $46.97 | 2021-2023 | Dificid, Zinplava |
| Fresenius Kabi USA, LLC | $43.04 | 2024 | Idacio |
| Boston Scientific Corporation | $42.38 | 2023-2025 | Endoarmor, Axonics |
| Braintree Laboratories, INC. | $38.53 | 2023 | Sutab |
| Alnylam Pharmaceuticals INC. | $37.19 | 2021-2024 | Givlaari |
| Aimmune Therapeutics, INC. | $29.26 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $26.46 | 2025 | Vegzelma |
| Astrazeneca Pharmaceuticals Lp | $20.93 | 2023 | Andexxa |
| Gilead Sciences, INC. | $20.74 | 2025 | |
| Medtronic, INC. | $20.00 | 2021 | |
| Intra-Sana Laboratories | $16.97 | 2022 | |
| Organon LLC | $14.39 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.14 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Papper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.